» Articles » PMID: 25061430

Treatment Satisfaction in Multiple Sclerosis

Overview
Journal Int J MS Care
Date 2014 Jul 26
PMID 25061430
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) are associated with inconvenient methods of administration, significant side effects, and low adherence rates. This study was undertaken to compare treatment satisfaction in MS patients treated with interferon beta-1a intramuscular (IFNβ-1a IM), interferon beta-1a subcutaneous (IFNβ-1a SC), glatiramer acetate (GA), and natalizumab (NTZ), and to examine the associations between treatment satisfaction ratings and adherence to therapy.

Methods: Two hundred twenty-six treated MS patients completed the Treatment Satisfaction Questionnaire for Medicine. Multivariable models were used to compare treatment satisfaction across groups.

Results: There were no statistically significant differences in overall treatment satisfaction. The NTZ group reported greater satisfaction with the ability of the medication to treat or prevent MS than the IFNβ-1a IM group. The NTZ group also reported higher overall convenience scores than the IFNβ-1a IM group and greater satisfaction with ease of use of the medication than the interferon and GA groups. Patients in the IFNβ-1a IM group reported less satisfaction with ease of planning when to use the medication than those in the other groups. Convenience was associated with adherence in IFNβ-1a SC- and GA-treated patients, with lower convenience scores associated with lower adherence.

Conclusions: These results may be useful to MS patients and health-care providers facing decisions about DMT use.

Citing Articles

The patient-reported wearing-off phenomenon with monoclonal antibody treatments for multiple sclerosis.

Marian L, Harris K, Conway D Mult Scler J Exp Transl Clin. 2024; 10(2):20552173241251707.

PMID: 38715893 PMC: 11075606. DOI: 10.1177/20552173241251707.


Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy.

Filippi M, Ferre L, Zanetta C, Rizzi C, Pessina G, Assogna F Front Neurol. 2024; 15:1379712.

PMID: 38638312 PMC: 11024245. DOI: 10.3389/fneur.2024.1379712.


Multicentre Observational Study of Treatment Satisfaction with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in the Arabian Gulf: The CLUE Study.

Inshasi J, Farouk S, Shatila A, Hassan A, Szolics M, Thakre M Neurol Ther. 2023; 12(4):1309-1318.

PMID: 37289421 PMC: 10310633. DOI: 10.1007/s40120-023-00497-2.


Disease-Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population.

Molazadeh N, Sahraian M, Ghajarzadeh M Caspian J Intern Med. 2023; 14(1):89-93.

PMID: 36741493 PMC: 9878908. DOI: 10.22088/cjim.14.1.89.


Home infusions of natalizumab for people with multiple sclerosis: a pilot randomised crossover trial.

Schultz T, Thomas A, Georgiou P, Juaton M, Cusack L, Simon L Ann Clin Transl Neurol. 2021; 8(8):1610-1621.

PMID: 34288591 PMC: 8351394. DOI: 10.1002/acn3.51410.


References
1.
Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P . The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2010; 18(1):69-77. DOI: 10.1111/j.1468-1331.2010.03110.x. View

2.
Gold R, Kappos L, Arnold D, Bar-Or A, Giovannoni G, Selmaj K . Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012; 367(12):1098-107. DOI: 10.1056/NEJMoa1114287. View

3.
Rio J, Porcel J, Tellez N, Sanchez-Betancourt A, Tintore M, Arevalo M . Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005; 11(3):306-9. DOI: 10.1191/1352458505ms1173oa. View

4.
Atkinson M, Sinha A, Hass S, Colman S, Kumar R, Brod M . Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004; 2:12. PMC: 398419. DOI: 10.1186/1477-7525-2-12. View

5.
Kleinschmidt-DeMasters B, Tyler K . Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005; 353(4):369-74. DOI: 10.1056/NEJMoa051782. View